Erratum: (Arteriosclerosis, Thrombosis, and Vascular Biology (2013) 33 (2097-2104) DOI: 10.1161/ATVBAHA.113.301799);Toll-like receptor 2/6 agonist macrophage-activating lipopeptide-2 promotes reendothelialization and inhibits neointima formation after vascular injury

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2097-2104

  Grote, Karsten ^a   Sonnenschein, Kristina ^a   Kapopara, Piyushkumar R ^a   Hillmer, Anja ^a   Grothusen, Christina ^b   Salguero, Gustavo ^a   Kotlarz, Daniel ^c   Schuett, Harald ^d   Bavendiek, Udo ^a   Schieffer, Bernhard ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

cytokines; endothelial growth factors; neointima formation; toll like receptors; vascular system injuries

Indexed keywords

BROXURIDINE; CYTOKINE; DEOXYURIDINE DERIVATIVE; EVANS BLUE; GROWTH FACTOR; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; IN VITRO STUDY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; REENDOTHELIALIZATION; REGENERATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 84883292338     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/01.atv.0000434992.46464.6a     Document Type: Erratum

References (41)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1:263.
2. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995;129:146-172.
3. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci (Lond). 2008;114:257-264. (Pubitemid 351294001)
4. Acharjee S, Cannon CP. Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. Crit Pathw Cardiol. 2010;9:203-206.
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. (Pubitemid 37174535)
6. Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res. 2011;90:417-427.
7. Kaisho T, Akira S. Regulation of dendritic cell function through toll-like receptors. Curr Mol Med. 2003;3:759-771. (Pubitemid 37536880)
8. Satoh M, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci. 2008;13:6708-6715.
9. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48:322-335. (Pubitemid 351975556)
10. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14:2592-2603.
11. Deiters U, Barsig J, Tawil B, Mühlradt PF. The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice. Exp Dermatol. 2004;13:731-739. (Pubitemid 39625219)
12. Macedo L, Pinhal-Enfield G, Alshits V, Elson G, Cronstein BN, Leibovich SJ. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol. 2007;171:1774-1788.
13. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, Kishimoto T, Nakanishi K, Fujimoto J. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology. 2005;41:443-450. (Pubitemid 40289490)
14. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature. 2010;467:972-976.
15. Mühlradt PF, Kiess M, Meyer H, Süssmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med. 1997;185:1951-1958. (Pubitemid 27247081)
16. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Mühlradt PF, Akira S. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol. 2000;164:554-557. (Pubitemid 30043671)
17. Takeuchi O, Kawai T, Mühlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol. 2001;13:933-940. (Pubitemid 32685205)
18. Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Mühlradt PF, Guzmán CA. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol. 2002;32:2857-2865. (Pubitemid 35238178)
19. Deiters U, Gumenscheimer M, Galanos C, Mühlradt PF. Toll-like receptor 2-and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun. 2003;71:4456-4462. (Pubitemid 36919912)
20. Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Mühlradt PF, Schieffer B. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood. 2010;115:2543-2552.
21. Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol. 2007;46:229-237. (Pubitemid 46127847)
22. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouché A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997;150:761-776. (Pubitemid 27073802)
23. Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007;116:163-173. (Pubitemid 47057522)
24. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796. (Pubitemid 23306123)
25. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010;9:830-834.
26. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
27. Watari M, Watari H, Nachamkin I, Strauss JF. Lipopolysaccharide induces expression of genes encoding pro-inflammatory cytokines and the elastindegrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Investig. 2000;7:190-198. (Pubitemid 30349165)
28. Vallejo JG. Role of toll-like receptors in cardiovascular diseases. Clin Sci (Lond). 2011;121:1-10.
29. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108:2905-2910. (Pubitemid 37517819)
30. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679-10684. (Pubitemid 38955802)
31. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115:3149-3156. (Pubitemid 41567579)
32. Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hartmann E, Barchet W, Wassmann S, Hartmann G, Nickenig G. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res. 2011;108:1358-1366.
33. Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, Zacharowski K. Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med. 2010;38:903-909.
34. Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A, White CW, Harken AH, Repine JE. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA. 1989;86:2516-2520. (Pubitemid 19102539)
35. Sato T, Yamamoto M, Shimosato T, Klinman DM. Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen. 2010;18:586-593.
36. Shingu K, Kruschinski C, Lührmann A, Grote K, Tschernig T, Von Hörsten S, Pabst R. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am J Respir Cell Mol Biol. 2003;28:316-321. (Pubitemid 36238008)
37. Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J, Märten A. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut. 2004;53:355-361. (Pubitemid 38241329)
38. Niebuhr M, Mühlradt PF, Wittmann M, Kapp A, Werfel T. Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice-a phase I trial in 12 patients. Exp Dermatol. 2008;17:1052-1056.
39. Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophageactivating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer. 2007;97:598-604. (Pubitemid 47339882)
40. Sawahata R, Shime H, Yamazaki S, Inoue N, Akazawa T, Fujimoto Y, Fukase K, Matsumoto M, Seya T. Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011;13:350-358.
41. Barrenschee M, Lex D, Uhlig S. Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs. PLoS One. 2010;5:e13889.